An international team of researchers, led by the University of Vienna and the Helmholtz Institute for Pharmaceutical Research ...

Q1 2025 Earnings Call Transcript May 13, 2025 Operator: Greetings and welcome to the Acurx Pharmaceuticals First Quarter 2025 ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...

Researchers have discovered saarvienin A, a novel glycopeptide antibiotic from a rare earth mine bacterium. It shows potent ...

aureus, including hard-to-treat infections caused by methicillin-resistant strains (MRSA), said Basilea. Ceftobiprole was turned down by the FDA in 2009 for ABSSSI, when the drug was partnered ...

The intravenous options for MRSA are generally limited to vancomycin, linezolid and TMP-SMX, although tigecycline and quinupristin–dalfopristin may have potential benefits. Ceftazidime 150 6 g 8 ...

New research suggests that outpatients with cancer are more likely than other outpatients to have antimicrobial-resistant bacterial pathogens.

Objective: To systematically evaluate the literature to determine whether vancomycin-induced neutropenia is dose- or duration-related and provide clinicians with feasible treatment alternatives.

Methicillin-resistant Staphylococcus aureus (MRSA) remains one of the most dangerous superbugs worldwide, with rising infection rates in both hospital and community settings. Even in sterile operating ...